TWIST1 and breast carcinoma: By using immunostaining of cytological samples of PBMCs, vimentin- and Twist-expressing cytokeratin-positive CTCs were identified in over 70% of pre-selected patients with early stage breast cancer and showing 88% positivity to cytokeratin staining, and in all patients with metastatic disease [160].